ATE553121T1 - Verbindungen zur veränderung der schleimsekretion - Google Patents

Verbindungen zur veränderung der schleimsekretion

Info

Publication number
ATE553121T1
ATE553121T1 AT04024019T AT04024019T ATE553121T1 AT E553121 T1 ATE553121 T1 AT E553121T1 AT 04024019 T AT04024019 T AT 04024019T AT 04024019 T AT04024019 T AT 04024019T AT E553121 T1 ATE553121 T1 AT E553121T1
Authority
AT
Austria
Prior art keywords
mucus secretion
compounds
altering
altering mucus
secretion
Prior art date
Application number
AT04024019T
Other languages
English (en)
Inventor
Yuehua Li
Kinda D Martin
Kenneth B Adler
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Application granted granted Critical
Publication of ATE553121T1 publication Critical patent/ATE553121T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04024019T 1999-02-24 2000-02-24 Verbindungen zur veränderung der schleimsekretion ATE553121T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25615499A 1999-02-24 1999-02-24

Publications (1)

Publication Number Publication Date
ATE553121T1 true ATE553121T1 (de) 2012-04-15

Family

ID=22971264

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00912034T ATE279206T1 (de) 1999-02-24 2000-02-24 Zusammensetzungen zur modulierung der schleimsekretion
AT04024019T ATE553121T1 (de) 1999-02-24 2000-02-24 Verbindungen zur veränderung der schleimsekretion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00912034T ATE279206T1 (de) 1999-02-24 2000-02-24 Zusammensetzungen zur modulierung der schleimsekretion

Country Status (10)

Country Link
EP (2) EP1538162B1 (de)
JP (2) JP5620037B2 (de)
AT (2) ATE279206T1 (de)
AU (1) AU766800B2 (de)
CA (1) CA2366951A1 (de)
DE (1) DE60014856T2 (de)
DK (2) DK1154786T3 (de)
ES (2) ES2391225T3 (de)
PT (1) PT1154786E (de)
WO (1) WO2000050062A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
PT1411967E (pt) * 2001-06-26 2011-09-30 Univ North Carolina State Péptido bloqueador que atua sobre a secreção de células inflamatórias
US6943021B2 (en) * 2002-06-07 2005-09-13 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
WO2006086681A2 (en) 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
JP2017504320A (ja) * 2013-12-20 2017-02-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 低剪断マイクロ流体デバイスならびにその使用および製造の方法
WO2016011301A1 (en) * 2014-07-17 2016-01-21 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for novel anticoagulants in the coagulation pathway
JP2022537318A (ja) 2019-06-17 2022-08-25 バイオマルク ファーマシューティカルズ リミテッド ぶどう膜炎の処置におけるペプチド及びその使用の方法
WO2022020985A1 (zh) * 2020-07-27 2022-02-03 上海市公共卫生临床中心 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用
EP4475866A4 (de) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptide und verfahren zur verwendung davon bei der behandlung von augenerkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
CA2093125C (en) * 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
EP0593580A4 (en) * 1991-06-20 1995-12-06 Us Health Sequences characteristic of human gene transcription product
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (de) * 1992-01-07 1993-07-14 National University Of Singapore Protein-Phosphatase-Inhibitoren zur Verwendung in der Therapie
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
JPH10502333A (ja) * 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド

Also Published As

Publication number Publication date
CA2366951A1 (en) 2000-08-31
EP1154786A2 (de) 2001-11-21
JP2015007065A (ja) 2015-01-15
ATE279206T1 (de) 2004-10-15
JP5620037B2 (ja) 2014-11-05
DK1154786T3 (da) 2005-02-14
WO2000050062A3 (en) 2000-12-21
AU3383300A (en) 2000-09-14
DE60014856D1 (de) 2004-11-18
ES2391225T3 (es) 2012-11-22
AU766800B2 (en) 2003-10-23
EP1538162B1 (de) 2012-04-11
DE60014856T2 (de) 2006-02-02
PT1154786E (pt) 2005-02-28
JP2002538783A (ja) 2002-11-19
WO2000050062A2 (en) 2000-08-31
EP1538162A3 (de) 2005-06-15
DK1538162T3 (da) 2012-07-23
EP1538162A2 (de) 2005-06-08
HK1041654A1 (en) 2002-07-19
ES2230078T3 (es) 2005-05-01
EP1154786B1 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
ATE553121T1 (de) Verbindungen zur veränderung der schleimsekretion
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
MY129356A (en) Electrospun pharmaceutical compositions
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
UA72884C2 (uk) Стабілізовані розчини паратирину
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
HRP20010119B1 (hr) Sprječavanje stvaranja sluzi u dišnim putevima primjenom antagonista egf-r
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
EP1186293A3 (de) Intermittierende Verabreichung eines Wachstumshormon-sekretionsförderers
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DK0528312T3 (da) Cykliske peptider og anvendelse deraf
DE69232323D1 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
DE69531944D1 (de) Neue hiv-protease-inhibitoren
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60019334D1 (de) Antivirale arznei
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
MXPA04003526A (es) Composicion y metodo para el tratamiento de la diabetes.
DE60135261D1 (de) Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
ES2064398T3 (es) Un nuevo antibiotico, mersacidina, un procedimiento para su preparacion y su utilizacion como medicamento.
KR960702754A (ko) 생리적으로 활성인 펩티드를 함유하는 질내 투여 제제(vaginal preparation containing physiologically active peptide)
TR199801298T2 (xx) ACE-engelleyicinin dispeptik semptomlar�n tedavisinde yeni t�bbi kullan�m�.
GB0028130D0 (en) Polypeptide and uses thereof
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.